Product R&D
Figure 1: Electron microscopic image of Ebola VLP vaccine. Dots represent immunostaining with antibodies that recognize Ebola surface glycoprotein.
During the past two decades a large number of outbreaks of infectious diseases have occurred in the United States and around the world. Many of the pathogenic agents involved in these outbreaks were previously unknown, while others reemerged in more invasive forms. The problem of emerging infectious diseases is further aggravated by the alarming increase in the rate of drug resistant infections and the growing threat of bioterrorism . Tackling this problem requires partnership between private industry and Government agencies. Based on this philosophy, and a strong portfolio of novel technologies, Integrated BioTherapeutics Inc (IBT) has forged strong partnerships with the government and industry partners to develop specific vaccines and therapeutics primarily for two important groups of emerging infectious diseases.